Crispr Therapeutics Ag (CRSP)

03:03 AM

FY2025 EPS Estimate for CRISPR Therapeutics Cut by Analyst - MarketBeat

03:03 AM

12:58 PM

Crispr therapeutics CEO sells $1.01 million in stock By Investing.com - Investing.com Nigeria

12:58 PM

Feb 21, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 3.4%Here's Why - MarketBeat

Feb 21, 2025

Feb 21, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 18,360 Shares - MarketBeat

Feb 21, 2025

Feb 21, 2025

Crispr therapeutics CEO sells $1.01 million in stock - Investing.com India

Feb 21, 2025

Feb 21, 2025

CRISPR Therapeutics AG CEO Samarth Kulkarni Sells Shares - TradingView

Feb 21, 2025

Feb 21, 2025

Stock Traders Purchase High Volume of CRISPR Therapeutics Call Options (NASDAQ:CRSP) - MarketBeat

Feb 21, 2025

Feb 21, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2%What's Next? - MarketBeat

Feb 21, 2025

Feb 21, 2025

Cantor Fitzgerald Has Weak Outlook for CRSP FY2025 Earnings - MarketBeat

Feb 21, 2025

Feb 21, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Lifted by Allworth Financial LP - MarketBeat

Feb 21, 2025

Feb 20, 2025

Crispr therapeutics COO Bruno Julianne sells $17,582 in stock By Investing.com - Investing.com South Africa

Feb 20, 2025

Feb 20, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap UpShould You Buy? - MarketBeat

Feb 20, 2025

Feb 20, 2025

CRISPR set to snap six days of gains as shares trade in red - MSN

Feb 20, 2025

Feb 20, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 4.1%Time to Sell? - MarketBeat

Feb 20, 2025

Feb 20, 2025

Market Whales and Their Recent Bets on CRSP Options - Benzinga

Feb 20, 2025

Feb 20, 2025

CRISPR Therapeutics: Navigating a Genetic Revolution Amid Healthcare Challenges - Reporteros del Sur -

Feb 20, 2025

Feb 20, 2025

CRISPR Therapeutics AG (CRSP): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 20, 2025

Feb 20, 2025

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq

Feb 20, 2025

Feb 20, 2025

Van ECK Associates Corp Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Feb 20, 2025

Feb 20, 2025

Crispr Therapeutics' general counsel sells shares worth $619,492 By Investing.com - Investing.com Australia

Feb 20, 2025

Feb 19, 2025

Crispr Therapeutics' general counsel sells shares worth $619,492 - Investing.com India

Feb 19, 2025

Feb 19, 2025

Crispr therapeutics COO Bruno Julianne sells $17,582 in stock - Investing.com

Feb 19, 2025

Feb 19, 2025

12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 19, 2025

Feb 19, 2025

CRISPR Therapeutics (CRSP) Projected to Post Earnings on Wednesday - MarketBeat

Feb 19, 2025

Feb 19, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4%Here's Why - MarketBeat

Feb 19, 2025

Feb 19, 2025

Cantor Fitzgerald Reiterates "Neutral" Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat

Feb 19, 2025

Feb 19, 2025

Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $74.50 - MarketBeat

Feb 19, 2025

Feb 18, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Given New $82.00 Price Target at Citigroup - MarketBeat

Feb 18, 2025

Feb 18, 2025

CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com Australia

Feb 18, 2025

Feb 18, 2025

CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year By Investing.com - Investing.com South Africa

Feb 18, 2025

Feb 18, 2025

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell? - Nasdaq

Feb 18, 2025

Feb 18, 2025

This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga

Feb 18, 2025

Feb 18, 2025

Morgan Stanley Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat

Feb 18, 2025

Feb 18, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by Evercore ISI to Outperform Rating - MarketBeat

Feb 18, 2025

Feb 17, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Outperform at Evercore ISI - MarketBeat

Feb 17, 2025

Feb 17, 2025

Research Analysts Offer Predictions for CRSP Q1 Earnings - MarketBeat

Feb 17, 2025

Feb 16, 2025

CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last? - MSN

Feb 16, 2025

Feb 16, 2025

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? - Benzinga

Feb 16, 2025

Feb 16, 2025

Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US - GlobeNewswire Inc.

Feb 16, 2025

Feb 16, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Given New $120.00 Price Target at Truist Financial - MarketBeat

Feb 16, 2025

Feb 16, 2025

Q1 Earnings Forecast for CRSP Issued By Leerink Partnrs - MarketBeat

Feb 16, 2025

Feb 16, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Sell at StockNews.com - MarketBeat

Feb 16, 2025

Feb 16, 2025

Stifel Nicolaus Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $49.00 - MarketBeat

Feb 16, 2025

Feb 16, 2025

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Feb 16, 2025

Feb 16, 2025

CRISPR Therapeutics (CRSP): Tailored Genetic Engineering - Securities.io

Feb 16, 2025

Feb 16, 2025

How to Take Advantage of moves in (CRSP) - Stock Traders Daily

Feb 16, 2025

Feb 15, 2025

Evercore ISI Group Upgrades CRISPR Therapeutics (LSE:0VRQ) - Nasdaq

Feb 15, 2025

Feb 15, 2025

Capital Advisors Inc. OK Buys 9,681 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Feb 15, 2025

Feb 15, 2025

BRIEF-Crispr Therapeutics AG shares open at $15 in debut, above IPO price of $14/shr - Wealth Management

Feb 15, 2025

Feb 15, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $32.00 at Morgan Stanley - MarketBeat

Feb 15, 2025

Feb 15, 2025

Stifel cuts CRISPR Therapeutics target to $49, holds rating - MSN

Feb 15, 2025

Feb 15, 2025

Why CRISPR Therapeutics (CRSP) Soared on Friday? - MSN

Feb 15, 2025

Feb 15, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Up Following Strong Earnings - MarketBeat

Feb 15, 2025

Feb 14, 2025

CRISPR Therapeutics (NASDAQ:CRSP) Given New $56.00 Price Target at Barclays - MarketBeat

Feb 14, 2025